SAN FRANCISCO, Nov. 3, 2025 — Leads & Copy — FibroGen, Inc. (NASDAQ: FGEN) will announce its third-quarter 2025 financial results on Monday, November 10, after the market closes. A conference call with the investment community will follow at 5:00 PM Eastern Time to discuss corporate and financial performance.
The FibroGen management team will host a conference call and webcast presentation, followed by a live Q&A. Access the live audio webcast here. For phone access, register here to receive dial-in details. A webcast replay will be available on FibroGen’s website.
FibroGen, Inc. focuses on developing novel therapies in cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is approved in China, Europe, Japan, and other countries for anemia treatment in chronic kidney disease (CKD) patients. The company is evaluating Phase 3 trial development for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (FOR46), an antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for metastatic castration-resistant prostate cancer, including FG-3180, a CD46-targeted PET biomarker.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
Source: FibroGen, Inc.
